Therapy Options in HR+/HER2- Breast Cancer

EP. 1: Frontline Treatment Strategies for HR+/HER2- Breast Cancer

ByHope S. Rugo, MD,Aditya Bardia, MD,Komal Jhaveri, MD,Mark D. Pegram, MD,Anne P. O’Dea, MD

June 27th 2022

Expert perspectives on the evolving treatment paradigm for patients receiving frontline therapy for HR+/HER2- breast cancer.

EP. 2: CKD4/6 Inhibition in HR+/HER2- BC: Trial Data With Abemaciclib and Ribociclib

ByHope S. Rugo, MD,Aditya Bardia, MD,Komal Jhaveri, MD,Mark D. Pegram, MD,Anne P. O’Dea, MD

June 27th 2022

Focusing on the frontline setting of HR+/HER2- breast cancer, panelists discuss clinical trial data with abemaciclib and ribociclib, respectively.

EP. 3: CKD4/6 Inhibition in HR+/HER2- BC: Trial Data With Palbociclib

ByHope S. Rugo, MD,Aditya Bardia, MD,Komal Jhaveri, MD,Mark D. Pegram, MD,Anne P. O’Dea, MD

July 4th 2022

Panelists share insight on clinical trial data behind use of palbociclib in the frontline setting of HR+/HER2- breast cancer.

EP. 4: HR+/HER2- BC: Selecting a CDK4/6 Inhibitor in the Frontline Setting

ByHope S. Rugo, MD,Aditya Bardia, MD,Anne P. O’Dea, MD,Komal Jhaveri, MD,Mark D. Pegram, MD

July 4th 2022

Taking into account all 3 available CDK4/6 inhibitors in HR+/HER2- breast cancer, experts consider how they’d select frontline therapy in this setting.

EP. 5: HR+/HER2- Breast Cancer: Identifying Barriers to Use of CDK4/6 Inhibition

ByHope S. Rugo, MD,Aditya Bardia, MD, MPH, FASCO,Komal Jhaveri, MD, FACP,Mark D. Pegram, MD,Anne P. O’Dea, MD

July 11th 2022

Comprehensive insight on the barriers to CDK4/6 inhibition in HR+/HER2- breast cancer, from both medical and accessibility perspectives.

EP. 6: Real-World Use of CDK4/6 Inhibition in HR+/HER2- Breast Cancer

ByHope S. Rugo, MD,Aditya Bardia, MD, MPH, FASCO,Komal Jhaveri, MD, FACP,Mark D. Pegram, MD,Anne P. O’Dea, MD

July 11th 2022

Experts home in on real-world data and resistance mechanisms to discuss practical use of CDK4/6 inhibition in HR+/HER2- breast cancer.v

EP. 7: Frontline Combination Strategies in HR+/HER2- BC

ByHope S. Rugo, MD,Aditya Bardia, MD, MPH, FASCO,Komal Jhaveri, MD, FACP,Mark D. Pegram, MD,Anne P. O’Dea, MD

July 18th 2022

A brief review of frontline combination strategies in the context of multiple driver pathways in HR+/HER2- breast cancer.

EP. 8: Is There a Role for CDK4/6 Inhibition in HR+/HER2+ Breast Cancer?

ByHope S. Rugo, MD,Aditya Bardia, MD, MPH, FASCO,Komal Jhaveri, MD, FACP,Mark D. Pegram, MD,Anne P. O’Dea, MD

July 18th 2022

Shifting their focus to the HR+/HER2+ setting of breast cancer, expert panelists consider the potential of CDK4/6 inhibition in light of clinical trial data.

EP. 9: Novel Treatment Approaches to Relapsed/Refractory HR+ Breast Cancer

ByHope S. Rugo, MD,Aditya Bardia, MD, MPH, FASCO,Komal Jhaveri, MD, FACP,Mark D. Pegram, MD,Anne P. O’Dea, MD

July 25th 2022

Comprehensive insight on novel treatment approaches in the setting of relapsed/refractory HR+/HER2- breast cancer, including oral SERDs, SERMs, and ER PROTAC degraders.

EP. 10: HR+ BC: Is There Still a Role for Everolimus Post–Endocrine Therapy?

ByHope S. Rugo, MD,Aditya Bardia, MD, MPH, FASCO,Komal Jhaveri, MD, FACP,Mark D. Pegram, MD,Anne P. O’Dea, MD

July 25th 2022

Panelists briefly consider the ongoing role of everolimus in relapsed/refractory HR+/HER2- breast cancer given recent shifts in the treatment paradigm.

EP. 11: Novel Therapy for Relapsed/Refractory HR+ BC: Oral SERDs

ByHope S. Rugo, MD,Aditya Bardia, MD, MPH, FASCO,Komal Jhaveri, MD, FACP,Mark D. Pegram, MD,Anne P. O’Dea, MD

August 1st 2022

A brief overview of oral SERDs currently being investigated in the setting of relapsed/refractory HR+/HER2- breast cancer.

EP. 12: Novel Therapy for Relapsed/Refractory HR+ BC: PI3K Inhibitors

ByHope S. Rugo, MD,Aditya Bardia, MD, MPH, FASCO,Komal Jhaveri, MD, FACP,Mark D. Pegram, MD,Anne P. O’Dea, MD

August 1st 2022

Expert perspectives on the current paradigm of PI3K inhibition in the setting of relapsed/refractory HR+/HER2- breast cancer.

EP. 13: Second-Line Use of CDK4/6 Inhibitors in HR+ Breast Cancer

ByHope S. Rugo, MD,Aditya Bardia, MD, MPH, FASCO,Komal Jhaveri, MD, FACP,Mark D. Pegram, MD,Anne P. O’Dea, MD

August 8th 2022

Shared insight on the potential role of CDK4/6 inhibitors in the second-line setting of relapsed/refractory HR+/HER2- breast cancer.

EP. 14: ADCs in HR+/HER2- Advanced BC: Results From TROPICS-02 and DESTINY-Breast04

ByHope S. Rugo, MD,Aditya Bardia, MD, MPH, FASCO,Komal Jhaveri, MD, FACP,Mark D. Pegram, MD,Anne P. O’Dea, MD

August 8th 2022

Centering discussion on the TROPICS-02 and DESTINY-Breast04 trials, panelists consider the advent of antibody drug conjugates in relapsed/refractory HR+ breast cancer.

EP. 15: Considerations for Use of ADCs in HER2-Low Breast Cancer

ByHope S. Rugo, MD,Aditya Bardia, MD, MPH, FASCO,Komal Jhaveri, MD, FACP,Mark D. Pegram, MD,Anne P. O’Dea, MD

August 15th 2022

A brief discussion on the use of antibody drug conjugates in patients with relapsed/refractory breast cancer and HER2-low expression.

EP. 16: Novel Therapy for Relapsed/Refractory HR+ BC: IO Therapy and PARP Inhibition

ByHope S. Rugo, MD,Aditya Bardia, MD, MPH, FASCO,Komal Jhaveri, MD, FACP,Mark D. Pegram, MD,Anne P. O’Dea, MD

August 15th 2022

Expert perspectives on trial results with both IO and PARP inhibitor therapy, respectively, in the setting of relapsed/refractory HR+/HER2- breast cancer.

EP. 17: Optimizing Management of HR+/HER2- BC: Future Directions in Care

ByHope S. Rugo, MD,Aditya Bardia, MD, MPH, FASCO,Komal Jhaveri, MD, FACP,Mark D. Pegram, MD,Anne P. O’Dea, MD

August 15th 2022

Closing out their discussion on HR+, HER2- breast cancer, expert panelists share their excitement for further evolution in the treatment paradigm.

Therapy Options in HR+/HER2- Breast Cancer

EP. 1: Frontline Treatment Strategies for HR+/HER2- Breast Cancer

EP. 2: CKD4/6 Inhibition in HR+/HER2- BC: Trial Data With Abemaciclib and Ribociclib

EP. 3: CKD4/6 Inhibition in HR+/HER2- BC: Trial Data With Palbociclib

EP. 4: HR+/HER2- BC: Selecting a CDK4/6 Inhibitor in the Frontline Setting

EP. 5: HR+/HER2- Breast Cancer: Identifying Barriers to Use of CDK4/6 Inhibition

EP. 6: Real-World Use of CDK4/6 Inhibition in HR+/HER2- Breast Cancer

EP. 7: Frontline Combination Strategies in HR+/HER2- BC

EP. 8: Is There a Role for CDK4/6 Inhibition in HR+/HER2+ Breast Cancer?

EP. 9: Novel Treatment Approaches to Relapsed/Refractory HR+ Breast Cancer

EP. 10: HR+ BC: Is There Still a Role for Everolimus Post–Endocrine Therapy?

EP. 11: Novel Therapy for Relapsed/Refractory HR+ BC: Oral SERDs

EP. 12: Novel Therapy for Relapsed/Refractory HR+ BC: PI3K Inhibitors

EP. 13: Second-Line Use of CDK4/6 Inhibitors in HR+ Breast Cancer

EP. 14: ADCs in HR+/HER2- Advanced BC: Results From TROPICS-02 and DESTINY-Breast04

EP. 15: Considerations for Use of ADCs in HER2-Low Breast Cancer

EP. 16: Novel Therapy for Relapsed/Refractory HR+ BC: IO Therapy and PARP Inhibition

EP. 17: Optimizing Management of HR+/HER2- BC: Future Directions in Care

Trending on OncLive

Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer

Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma

Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies

Nuvisertib Yields Strong Safety, Promising Efficacy in R/R Myelofibrosis

FDA Approves Larger Vial Size for Nelarabine Injection in T-ALL and T-LBL